Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied
Checked against the public recordLast updated Oct 28, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- R-Pharm
- Interventions being studied
- Drug: Ixabepilone; Drug: Cisplatin; Drug: Ixabepilone; Drug: Cisplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Escalation Phase Subjects: Primary solid tumor not curable by local measures such as surgery, radiation Inclusion Criteria: * Men and women age ≥ 18 Exclusion: * More than 2 prior chemotherapy containing regimens for metastatic disease * No prior exposure to cisplatin or ixabepilone Expansion Phase Subjects: Advanced Non-small cell lung cancer Inclusion Criteria: * Men and women age ≥ 18 Exclusion: * No prior chemotherapy-containing regimen for metastatic disease * No prior exposure to cisplatin or ixabepilone
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Georgetown University Medical CenterWashington D.C., District of Columbia
- The Cancer Institute Of New JerseyNew Brunswick, New Jersey
- Penn State Milton S. Hershey Medical CenterHershey, Pennsylvania
- Local InstitutionLucca
- Local InstitutionMeldola (Fc)
- Local InstitutionRimini
- Local InstitutionViterbo
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 28, 2020. Always confirm current availability with the study team.